Sign In
Step 1
Draft
Step 2
Unite with Fellow Investors
Step 3
Choose the Best Attorney
Step 4
Provide Documents
Step 5
Follow Case Progress
Step 6
Get Payout
BDX.US
id: 2382

Becton, Dickinson and Company ($BDX) $175 Million SEC Fair Fund

Eligible claimants can submit their claims for compensation.
$175,000,000
Cash Settlement
SEC
Court
3-22361
Case number
02/05/2019
Class period Start
02/05/2020
Class period End
12/13/2026
Claim deadline

The SEC established a $175 million Fair Fund for investors harmed by Becton Dickinson’s misleading statements about regulatory and safety risks affecting its Alaris infusion pump and its improper accounting for remediation costs.

Outline:

Becton Dickinson sold its Alaris infusion pump while dealing with significant software and regulatory issues. The SEC found that BD did not adequately disclose the risk that FDA requirements could prevent continued sales of the product. BD also overstated its financial results by failing to properly account for remediation costs. BD paid a $175 million civil penalty that is now being distributed to harmed investors through an SEC Fair Fund.

Timeline:

  • October 31, 2019: The FDA rejected BD’s proposed approach for Alaris and warned that the device had defects and safety issues that needed to be addressed.

  • November 5, 2019: BD told investors that Alaris shipments were being delayed for software improvements while maintaining financial forecasts that assumed most lost sales would be recovered later in the year.

  • November 27, 2019: BD filed its annual report without recording approximately $59 million in estimated Alaris remediation costs, which the SEC found overstated the company’s financial results.

  • January 14, 2020: BD told investors that Alaris shipments had resumed and reaffirmed its 2020 revenue guidance.

  • January 23, 2020: BD again stopped shipping Alaris after the FDA raised concerns about the company resuming sales without addressing significant safety issues.

  • February 6, 2020: BD disclosed that it needed new FDA clearance for Alaris and would stop selling the device to new customers until approval was obtained; BDX shares fell about 12%.

  • December 16, 2024: The SEC ordered BD to pay a $175 million civil penalty and established a Fair Fund for harmed investors.

Background:

Becton Dickinson’s Alaris infusion pump was an important product for the company, contributing approximately 10% of its profits. From 2016 through early 2020, BD became aware that Alaris required additional FDA clearance to address historical changes to the device and multiple software problems that posed potential safety risks.

By 2019, BD was tracking more than 160 software issues, increasing to more than 200 by August. More than 25 were categorized by BD experts as presenting the greatest potential harm to patients. In October 2019, the FDA warned BD that continuing to sell Alaris with unresolved defects and safety problems was not acceptable.

The SEC found that BD nevertheless gave investors the impression that the Alaris problems involved routine software improvements and that the interruption in sales would be temporary. The company did not adequately disclose the possibility that it might be unable to resume normal sales until it received new FDA clearance.

BD also failed to properly account for the expected cost of fixing Alaris. By November 2019, the company estimated remediation costs at approximately $59 million but did not record those costs as required, resulting in an overstatement of its reported financial results.

In January 2020, BD resumed shipments but later stopped them again after further discussions with the FDA. On February 6, the company told investors that new FDA clearance would be required and lowered its financial guidance. BDX shares fell approximately 12% that day.

The SEC later found that BD’s disclosure and accounting failures harmed investors. BD paid a $175 million civil penalty, which now makes up the SEC Fair Fund available for distribution to eligible harmed investors.

What Can Investors Expect Now?

The SEC established a $175 million Fair Fund for investors harmed by Becton Dickinson’s misleading statements about regulatory and safety risks affecting its Alaris infusion pump and its improper accounting for remediation costs.

If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section.

Case Type
SEC Fair Fund
Case Status
Accepting Claims
Alleged Offence
Misleading Statements, 
Financial Misrepresentation, 
Fraud, 
Failure to Disclose, 
Omissions
Suspected Party
Other
Security Type
Stocks
Trade Direction
Long
Filing date
12/16/2024
Plaintiffs
U.S. Securities and Exchange Commission (SEC)
Attorneys
SEC administrative enforcement proceeding
Defendants
Becton, Dickinson and Company
Administrator
JND Legal Administration
Trades matching type
FIFO

Frequently Asked Questions